REG - GENinCode PLC - Directorate Change

GenincodeAnnouncement

29/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211129:nRSc8040Ta&default-theme=true

RNS Number : 8040T  GENinCode PLC  29 November 2021

29 November 2021

 

GENinCode Plc

("GENinCode" or the "Company")

 

Directorate change

 

GENinCode Plc (AIM: GENI), the predictive genetics company focused on the
prevention of cardiovascular disease, announces that David Evans,
Non-Executive Director, has notified the Board of his intention to stand down
from his role with immediate effect.

 

Bill Rhodes, Non-Executive Chairman of GENinCode Plc said: "We would like to
thank David for his invaluable contribution to GENinCode during his tenure.
David has worked with members of the GENinCode management team for many years,
and he has always provided instrumental strategic advice and counsel from his
wealth of experience in the sector. On behalf of the Board, I would like to
wish him the very best for the future."

 

For further information please contact:

 

 GENinCode Plc                          www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                  Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)   Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)
 Walbrook PR Limited

                                        Tel: 020 7933 8780 or genincode@walbrookpr.com
 Anna Dunphy / Paul McManus / Louis Ashe-Jepson

 

 

About GENinCode plc

 

GENinCode plc is engaged in the risk assessment, prediction and prevention of
cardiovascular disease ("CVD"). CVD is the leading cause of death worldwide
accounting for approximately 18 million deaths annually. The Company's
products and technology have been developed with the aim of predicting the
onset of CVD and providing a personalised treatment pathway for patient
management. Its products have been the subject of clinical studies on over
75,000 patients to assess and predict the onset of CVD.

 

The Company was incorporated in September 2018 to acquire the assets,
intellectual property and know-how of the Ferrer inCode and Gendiag.exe
businesses, which were then part of Grupo Ferrer Internacional S.A., a large
Spanish multinational private pharmaceutical and healthcare company. The
technology and products acquired included Cardio inCode®, Lipid inCode®,
Thrombo inCode® and Sudd inCode®. Approximately €50 million has been
invested in the research and development of these products since 2007. The
Company has begun to commercialise these products in Europe and is also
targeting the UK and US.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUWRORAVUAUUA